Floatz logo

Survaxm

Lung Typical Carcinoid Tumor

Roswell Park Cancer InstitutevaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Lung Typical Carcinoid Tumor cohort.

Asset / SponsorPhaseRating
Temsirolimus
National Cancer Institute (NCI)
Phase 2BB
gw786034
National Cancer Institute (NCI)
Phase 2B
Regorafenib
University of Southern California
Phase 2B
Romidepsin
National Cancer Institute (NCI)
Phase 2CCC
DOTATOC
British Columbia Cancer Agency
Phase 2CCC

View all 16 →

Same molecule, other indications

Survaxm is also rated in:

glioblastomaDormant
CCC
Indicative ·
55 / 100
View asset →
lung neuroendocrine neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →